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An 84-year-old man was referred to our hospital with swollen right cervical lymph nodes. Computed
tomography showed right supraclavicular and mediastinal lymph node enlargement, and ﬂuorodeoxyglucose
positron emission tomography showed multiple areas of abnormally increased radioactivity in the right
supraclavicular and mediastinal lymph nodes, right ninth rib, and left ﬁfth and seventh ribs. Biopsy of the
right supraclavicular lymph node revealed metastatic adenocarcinoma with partial immunohistochemical
staining for prostate speciﬁc antigen (PSA). Serum PSA levels were not elevated (2.01 ng/ml). An 8-core
transrectal prostatic biopsy was negative. Thus, we could not determine the primary site of the
adenocarcinoma. The patient was diagnosed with carcinoma of an unknown primary site and followed
without chemotherapy. Four years later, he was referred to our hospital due to right hydronephrosis.
Serum PSA level was 31. 1 ng/ml. The tumor was not palpable by rectal examination. A 12-core
transrectal prostatic biopsy revealed a poorly differentiated adenocarcinoma. Computed tomography
revealed metastases in the left axilla, para-aortic, and pelvic lymph nodes as well as in the lung. We
diagnosed the patient with prostate cancer, and combined androgen blockade (CAB) was administered.
Metastases in the lymph nodes, lung, and bone were reduced on imaging after 1 month of therapy.
Therefore, a deﬁnitive diagnosis of prostate cancer T1cN1M1c was made. Dutasteride had been
administered as a benign prostate hyperplasia treatment 2 years before his ﬁrst visit, which may have made
the deﬁnitive diagnosis of prostate cancer difﬁcult. In contrast, dutasteride may have delayed the
progression of prostate cancer in this patient.
(Hinyokika Kiyo 64 : 187-192, 2018 DOI : 10.14989/ActaUrolJap_64_4_187)











































Fig. 2. Computed tomography of right supracla-
vicular (a), mediastinal (b), and pelvic lymph
nodes.
泌62,08,0◆-3
Fig. 3. FDG-PET of the ribs and right supracla-





患 者 : 84歳，男性














初診時検査所見 : WBC 4,500/ul，Hb 14.1 g/dl，Plt
18.3×104/μ l，TP 7.8 g/dl，Alb 4.13 g/gl，ALP 265
IU/l，AST 45 IU/l，ALT 38 IU/l，LDH 249 IU/l，T-
Bil 0.4 mg/dl，BUN 15 mg/dl，Cre 0.6 mg/dl，Na 139
mEq/l，K 4.2 mEq/l，Cl 99 mEq/l，CRP 0.02 mg/dl，
PSA 2.01 ng/ml，NSE 11.4 ng/ml，CEA 2.1 ng/ml，
CA19-9 19.8 U/ml，IL-2R 377 U/ml
右鎖骨上窩リンパ節 CT ガイド下生検 : HE 染色に
て異型細胞が篩状構造で増殖浸潤する腺癌（Fig. 1a）
が認められ Gleason’s score 4＋4 相当であった．免疫
染色では PSA 弱陽性（Fig. 1b）を示し前立腺癌転移
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Table 1. Clinical course and PSA levels
泌62,08,0◆-T1
Table 2. Diameter measurements of the largest lesion in the
right supraclavicular lymph node (a). Sum of dia-






画像所見 : 造影 CT では右鎖骨上窩，縦隔，左肺門
部リンパ節に 10∼20 mm 大の腫脹（Fig. 2）を認め
た．骨盤内リンパ節に異常は認めなかった．FDG-
PET でも同部位に SUV max＝6.26 の集積を認めた．
また右第 9，左第 5，7肋骨に SUV max＝4.19 の集










本症例の臨床経過および PSA 推移について Table 1
に示す．PSA は2009年11月のデュタステリド開始後
から低下し始めた．およそ 3年間かけてベースライン
の 11.6 ng/ml から2012年 9月の nadir 値 1.27 ng/ml
まで約89％低下した．頸部リンパ節腫瘤および全リン
パ節腫瘤最大径の和の推移について Table 2 に示す．
腫瘍は PSA の低下に合わせて縮小を示したが2012年
12月頃から PSA が上昇に転じた後は腫瘍も増大傾向





Fig. 4. HE (a) and immunohistochemical staining





Fig. 5. Immunohistochemical staining for the and-
rogen receptor of the right supraclavicular




縦隔腫瘍に対し放射線療法 50 Gy が施行された．結
果，腫瘍は縮小し浮腫も軽快した．










で左葉 2本，右葉 4本から PSA 免疫染色一部陽性を
示す低分化腺癌Gleason’s score 4＋5（Fig. 4a，b）を検
出した．血清テストステロンは 11.2 ng/ml と軽度高
値であった．CAB（ビカルタミド 80 mg/day，リュー
プロレリン酢酸塩 3.75 mg/month）を開始し，右第 9
肋骨転移巣に対しては放射線治療を施行した． 1カ月


























































































症候性 stage D 前立腺癌患者に対してフィナステリド
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